Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Solid Tumors 2Solid Tumor, Adult 2Advanced Solid Tumors 2Advanced Solid Tumor 2Advanced Refractory Solid Tumors 2Urinary Bladder Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Mesothelioma, Malignant 1Melanoma 1MSI-H Advanced Colorectal Cancer 1Immune-related Adverse Event 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Malignant Solid Tumors 1Advanced Malignant Solid Tumor 1

Interventions

pembrolizumab 7Radiotherapy 3Proton Therapy 3Interleukin-2 3Cyclophosphamide 3spartalizumab 2fludarabine 2Rosuvastatin Calcium 2Paclitaxel 2Ipilimumab 2Immune Checkpoint Inhibitors 2Cetuximab 2Carboplatin 2Blood Specimen Collection 2toripalimab 1tislelizumab 1sotorasib 1peposertib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1niraparib 1neotil 1necitumumab 1mirdametinib 1leronlimab 1lenvatinib 1atezolizumab 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Solid Tumor, Adult × Immune Checkpoint Inhibitors × Other solid neoplasm × Clear all
NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

ImmuneSensor Therapeutics Inc.

Phase 1/2 Completed
40 enrolled 16 charts
Other solid neoplasm

Solid Tumor, Adult

NCT06026254 2024-11-18

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

ImmuneSensor Therapeutics Inc.

Phase 1 Active not recruiting
2 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡